We upgrade our recommendation on PerkinElmer, Inc. (PKI) to Outperform based on its third quarter results. Earnings per share of $0.45 surpassed the Zacks Consensus Estimate by a penny. PerkinElmer is a leader in several life science segments.
It has added new related areas as part of its reorganization and divested unrelated businesses. As a consequence, it has emerged as a higher-growth, higher-margin company. Its operations, both sales and manufacturing, are diversified on a geographic basis. The company has implemented cost containment measures. Growing recurring revenue stream and operating margin expansion are its pillars of strength.
In the end, our Outperform recommendation is supported from a valuation perspective and a favorable risk-reward tradeoff. Based on the company's recent performance, we upgrade our price target to $38.00, which is based on a P/E of approximately 18.4x our 2012 EPS estimate.
PERKINELMER INC (PKI): Free Stock Analysis Report
To read this article on Zacks.com click here.